|
|
테두리
|
|
 |
YQjsmtoUrGlRPHiHtSM |
 |
387 |
|
 |
| Can I take your number? http://planetsuzy.fun/ planet suzy The Phase III trial compared Yervoy (ipilimumab) to placebo following radiation in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel. The 799-patient study’s primary endpoint of overall survival did not reach statistical significance (11.2 months versus 10 months for placebo) but anti-tumour activity “was observed across some efficacy endpoints, including progression free-survival”, B-MS noted. More data will be presented at the European Cancer Congress in Amsterdam at the end of the month. |
|
 |
Chance |
 |
2019-12-05 01:49:17 |
|
|
|
|
|
|
|
|
|
